A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies.

Ian W. Flinn, Albert S. Yu, Steven Coutré et al.|Journal of Clinical Oncology|2011

Cited by 18